ClinicalTrials.gg
Not yet recruitingNCT07875920Updated Oct 15, 2026

Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation

A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC) and Colorectal Adenocarcinoma, sponsored by Neowise Biotechnology. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Neowise Biotechnology · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Adenocarcinoma of Lung with a site in China — 38 open to participants now, 41 under way, 9 of them phase 3. Adenocarcinoma of Lung · China.

Planned enrollment
30th of 57
66 · median 69
Started
2026
with 5 others
Phase 1
6 of 88
4 open now
Primary completion
2030-03
later than 38 of 40 live
Registered
86th of 88
by date

Among the 88 studies in Adenocarcinoma of Lung with a site in China, this one is the 30th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 38 of the 40 other live ones, and was the 86th registered.

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.

Browse Adenocarcinoma of Lung studies →

Open to participants now

38 of the 88 studies in Adenocarcinoma of Lung with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Adenocarcinoma of Lung with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of NW-301V, an autologous TCR-T cell therapy, in Chinese adult participants with advanced malignant solid tumors harboring a KRAS G12V mutation.

Read the detailed description

There are 2 parts in this study:

  • Phase 1a: Dose Escalation. A conventional 3+3 dose escalation design will be used to assess the safety/tolerability, pharmacokinetics (PK) and preliminary antitumor activity of NW-301V in participants with advanced or locally unresectable solid tumors who meet the enrollment criteria. A provisional Recommended Phase 2 Dose (RP2D) of NW-301V will be determined.
  • Phase 1b: Dose expansion. Participants with pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma (CRC) or lung adenocarcinoma (LUAD) who meet the eligibility criteria will be enrolled into three separate disease-specific cohorts. The final RP2D will be determined.

Participants who meet the protocol-defined eligibility criteria during screening will undergo leukapheresis for the manufacture of NW-301V. Prior to NW-301V infusion, participants will receive a lymphodepletion (LD) regimen consisting of fludarabine and cyclophosphamide. Participants will be closely monitored for safety, tolerability and treatment response throughout the study.

03

Conditions studied

  • Advanced Solid Cancer
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Colorectal Adenocarcinoma
  • Lung Adenocarcinoma
  • KRAS G12V
  • Pancreatic Cancer
  • Colorectal Cancer

Keywords

  • TCR-T
  • TCR-T cell therapy
  • PDAC
  • CRC
  • LUAD
  • Pancreatic cancer
  • Colorectal cancer
  • NSCLC
  • KRAS
  • KRAS G12V
  • HLA-A*11:01
  • Solid tumors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Applicable to both Phase 1a and 1b:

  • Age between 18-75 years
  • HLA-A*11:01 positive
  • Tumor confirmed to have KRAS G12V mutation
  • At least one according to 1.1
  • 0-1
  • > 3 months before leukapheresis
  • Adequate organ functions prior to leukapheresis and lymphodepletion

For Phase 1a only:

  • or pathologically confirmed, advanced or unresectable solid tumors including, but not limited to, pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma (CRC), and lung adenocarcinoma (LUAD)
  • Participants must have no standard treatment options available or are unable to tolerate currently available standard treatment

For Phase 1b only:

  • Cohort A: Histologically or pathologically confirmed advanced or locally advanced unresectable PDAC that had failed or progressed after at least 1 line of prior systemic therapy
  • Cohort B: Histologically or pathologically confirmed advanced CRC that had failed or progressed after at least 2 lines of prior systemic therapies
  • Cohort C: Histologically or pathologically confirmed advanced LUAD that had failed or progressed after at least 1 line of prior systemic therapy

(Additional protocol-defined Inclusion criteria may apply)

Key Exclusion Criteria:

Applicable to both Phase 1a and 1b:

  • Received the following treatments: Cytotoxic chemotherapy or agents within 2 weeks prior to leukapheresis, or within 1 week prior to lymphodepletion; Antibodies or other biologic therapy within 3 weeks prior to leukapheresis, or within 2 weeks prior to lymphodepletion;
  • History of allergic reactions to cyclophosphamide, fludarabine, or any other chemical or biological components of the drugs used in this study
  • History of chronic or recurrent severe disease, or active immune disease requiring treatment with or other immunosuppressive agents within 1 year prior to leukapheresis or lymphodepletion
  • Have symptomatic
  • Have or carcinomatous meningitis
  • Have ongoing or active infection
  • Breastfeeding or pregnant

(Additional protocol-defined Inclusion criteria may apply)

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    NW-301V

    Participants receive lymphodepletion and a single infusion of NW-301V, an autologous TCR-T cell therapy targeting KRAS G12V. In Phase 1a (dose escalation), two dose levels at 4×10\^9 (±30%) and 8×10\^9 (±30%) TCR-T+ cells will be tested. In Phase 1b (dose expansion), NW-301V will be administered at provisional RP2D in 3 tumor-specific cohorts (Cohort A: pancreatic ductal adenocarcinoma; Cohort B: colorectal adenocarcinoma; Cohort C: lung adenocarcinoma), each containing around 20 participants.

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: NW-301V

Interventions

  • Used for lymphodepletion

  • Used for lymphodepletion

  • BiologicalNW-301V

    NW-301V is an autologous TCR-T cell therapy targeting KRAS G12V in the context of HLA-A\*11:01, administered intravenously after lymphodepletion.

06

What researchers measure

Primary outcomes

  1. Phase 1a: Safety and tolerability of NW-301V in participants with advanced solid tumors

    Type, frequency, and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), abnormalities in vital signs, electrocardiograms (ECGs) and other laboratory results.

    Time frame: Through the study completion, an average of 2 years

  2. Phase 1a: Maximum tolerated dose (MTD, if applicable) and provisional Recommended Phase 2 Dose (RP2D)

    Number of participants with dose-limiting toxicities (DLTs) and their types.

    Time frame: 28 days

  3. Phase 1b: Safety and tolerability of NW-301V in PDAC, CRC and LUAD respectively under provisional RP2D

    Type, frequency, and severity of TEAEs, SAEs, and abnormalities in vital signs, ECGs and other laboratory results.

    Time frame: Through the study completion, an average of 2 years

  4. Phase 1b: Final RP2D of NW-301V

    Determine the final RP2D of NW-301V

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective response rate (ORR)

    Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)

    Time frame: Through the study completion, an average of 2 years

  2. Disease control rate (DCR)

    Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)

    Time frame: Through the study completion, an average of 2 years

  3. Duration of response (DOR)

    Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)

    Time frame: Through the study completion, an average of 2 years

  4. Progression-free survival (PFS)

    Assessed by RECIST v1.1. (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)

    Time frame: Through the study completion, an average of 2 years

  5. Overall survival (OS)

    (Phase 1a: in the entire cohort; Phase 1b: in PDAC, CRC and LUAD respectively)

    Time frame: Through the study completion, an average of 2 years

  6. Maximum blood concentration (Cmax) of NW-301V

    Time frame: Through the study completion, an average of 2 years

  7. Time to maximum concentration (Tmax) of NW-301V

    Time frame: Through the study completion, an average of 2 years

  8. Persistence of NW-301V TCR-T cells in vivo

    Determined by qPCR-measured gene copies

    Time frame: Through the study completion, an average of 2 years

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2030, 41 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 15, 2026
StartEst.
Oct 2026
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2033
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07875920
Lead sponsor
Neowise Biotechnology
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2030 (estimated)
Completion
Mar 2033 (estimated)
Last update
Oct 15, 2026

Study contacts

Rui Liu, Master Degree
Contact
rui.liu@neowisebio.com
+86-512-67991566

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NW-301V

Start the discussion